Key parameters of measles virus production for oncolytic virotherapy

Katja Weiss, Denise Salzig, Michael D. Mühlebach, Klaus Cichutek, Ralf Pörtner & Peter Czermak
Attenuated measles virus has revealed selective tumor cell killing and is currently tested in clinical trials for the therapy of cancer patients. The amount of infectious particles per dose needed for oncolytic therapy can be more than a million times higher compared to vaccination. This requires highly effective production processes which guarantee the measles virus quantities needed for its use in cancer therapy. Referring to measles virus production itself, several factors are influencing process parameters...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.